Unified AI For
Diagnostic Imaging,
Built Across Every Organ System.
Under active validation Designed for clinical-grade deployment across enterprise radiology..
Under active validation
Accuracy
Multi-site validation planned Q3 2026
Analysis Time
Patent-protected architecture.
6 Organ Systems
One Engine. Six Organ Systems.
3D MRI or CT scan
(NIfTI / DICOM)
Probabilistic Masking
Multimodal Embedding
RL Feedback Loop
- Confirmed Condition ICD-10
- Severity Volume cm³
- Confidence Score 96.4%
Locus.Brain
9 diseases
In DevelopmentLocus.Heart
Cardiac AI
RoadmapLocus.Lungs
Pulmonary AI
RoadmapLocus.Liver
Hepatic AI
RoadmapLocus.Spine
Spinal AI
RoadmapLocus.Pancreas
Pancreatic AI
RoadmapThe Minds Behind the Intelligence
Lucas Lee Stamatis
Chief Executive Officer
Serial entrepreneur and SMU-trained finance professional with a track record across private healthcare and pharmacy ventures. Leads Stamatis.AI’s commercial strategy and hospital system partnerships, bringing institutional-grade financial discipline to one of the most capital-intensive sectors in tech.
Sajed Khan
Co-Founder & CTO
Security architect and CISO with deep expertise in HIPAA compliance, healthcare data infrastructure, and enterprise risk management. Co-inventor of US Patent 19/200,539. Architected Stamatis.AI’s 3-stage probabilistic masking pipeline with security and clinical-grade data integrity built in from the ground up.
Dr. Rao K. Ali, MD
Chief Medical Officer
Board Certified Interventional Pain Specialist. CEO of Premier Pain Centers across 13 Texas locations.
Aviraj (Avi) Sinha, PhD
Co-Founder & Chief Data Scientist
PhD in AI, machine learning, and quantum computing from Southern Methodist University. Co-inventor of US Patent 19/200,539. Leads the model architecture and validation strategy behind Stamatis.AI’s diagnostic engine — combining classical deep learning with next-generation computational methods to set a new standard for clinical AI performance.
Built for Scale.
We are currently in a high-growth phase, backed by patent-protected IP and clinical partnerships with leading medical institutions.
Status
Series A
Funding Round
IP Portfolio
Patent Pending
US 19/200,539